Skromne KG, Hidalgo RR

Language: Spanish
References: 4
Page: 156-157
PDF size: 613.95 Kb.

ABSTRACT

We label methylene blue with radionuclides beta and gamma. This new radiopharmaceutical was probed in experimental animal for radiochromatography, radiotoxicity and genetics; after that we take scans in 12 patients with gastric reflux (six of them with Barrett’s disease), in 3 selected cases we probed the therapeutical effect of methylene blue with beta emission. All the patients were controlled with six months of clinical and laboratorial follow-up without harmless or adverse reaction to the new compound. Because of the good results, we propose the new radiopharmaceutical and method for the diagnoses, control and treatment of Barrett’s esophagus.

REFERENCES

1. Bremner C, Bremner R. Barrett’s esophagus. Surg Clin North Am 1997; 77: 1115.

2. Canto MF. Methylene blue staining predicts dysplasia in Barret’s esophagus. Gastrointest Endosc 1999; 49(AB): 50.

3. Richardson WX, True TLL, Hunter TG. Laparoscopic antireflux surgery. Surg Clin North Am 1996; 76: 437.

4. Alvarez CJ, Skromne-Kadlubik G. Label of DDD-131. J Inter applied Isotopes 1973; 24: 187.